Related Experiment Video
Updated: Mar 15, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors
Maria Umlauft1,2, Piotr Radojewski1, Petar-Marko Spanjol1
1Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
Abstract:
We aimed to assess the risk of developing diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors (NETs).
Methods:
NET patients received somatostatin radiopeptide therapy with 90Y-DOTATOC or 177Lu-DOTATOC. The incidence of diabetes mellitus and its mortality were assessed using univariate and multivariate regression.
Results:
Overall, 1,535 NET patients were enrolled and received 3,807 treatment cycles. After treatment, 72 patients developed diabetes mellitus, including 47 cases after 90Y-DOTATOC and 25 cases after combined treatment. The diabetes mellitus risk was higher before than after DOTATOC (estimate, 0.0032; P < 0.001), and overall survival was similar in patients with and without diabetes mellitus (hazard ratio, 1.13; 95% confidence interval, 0.91-1.39; n = 1,535; P = 0.27).
Conclusion:
Radiopeptide therapy does not appear to increase the risk of developing diabetes mellitus in NET patients, whereas diabetes mellitus does not appear to increase the mortality of NET patients undergoing receptor-targeted radiopeptide therapy.
Insights
Radiopeptide therapy for neuroendocrine tumors (NETs) does not increase diabetes mellitus risk. Diabetes mellitus also does not affect overall survival in NET patients receiving this treatment.
Area of Science:
- Oncology
- Endocrinology
- Nuclear Medicine
Background:
- Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms.
- Radiopeptide therapy is a targeted treatment for NETs using radiolabeled somatostatin analogs.
Purpose of the Study:
- To evaluate the risk of developing diabetes mellitus after radiopeptide therapy for NETs.
- To assess the impact of diabetes mellitus on all-cause mortality in NET patients post-treatment.
Main Methods:
- A cohort of 1,535 NET patients receiving 3,807 cycles of 90Y-DOTATOC or 177Lu-DOTATOC therapy were analyzed.
- Incidence of diabetes mellitus and mortality were assessed using univariate and multivariate regression analyses.
Main Results:
- 72 patients developed diabetes mellitus post-treatment; the risk was higher before DOTATOC therapy.
- Overall survival was comparable between NET patients with and without diabetes mellitus (HR 1.13, P=0.27).
Conclusions:
- Radiopeptide therapy for NETs does not elevate the risk of developing diabetes mellitus.
- Diabetes mellitus does not appear to increase all-cause mortality in NET patients undergoing receptor-targeted radiopeptide therapy.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
